Baird Highlighgs NewLink Genetics' (NLNK) IDO Program Amid Algenpantucel-L Failure
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
NewLink Genetics Announces Results from Phase 3 IMPRESS Trial of Algenpantucel-L for Patients with Resected Pancreatic Cancer
May 9, 2016 4:01 PM EDTManagement to Host Conference Call
Tuesday, May 10th at 8:30 a.m. ET
AMES, Iowa, May 09, 2016 (GLOBE NEWSWIRE) -- Â NewLink Genetics Corporation (NASDAQ: NLNK) announced today results of its Phase 3 clinical trial for algenpantucel-L for patients with resected pancreatic cancer.Â
The IMPRESS Phase 3 study of algenpantucel-L for patients with resected pancreatic cancer did... More
